Cargando…

Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis

INTRODUCTION: Pharmacovigilance (PV) is designed to monitor drugs continuously after their commercialization, assessing and improving their safety profile. The main objective is to increase the spontaneous reporting of adverse drug reactions (ADRs), in order to have a wide variety of information. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Giofrè, Chiara, Scicchitano, Francesca, Palleria, Caterina, Mazzitello, Carmela, Ciriaco, Miriam, Gallelli, Luca, Paletta, Laura, Marrazzo, Giuseppina, Leporini, Christian, Ventrice, Pasquale, Carbone, Claudia, Saullo, Francesca, Rende, Pierandrea, Menniti, Michele, Mumoli, Laura, Chimirri, Serafina, Patanè, Marinella, Esposito, Stefania, Cilurzo, Felisa, Staltari, Orietta, Russo, Emilio, De Sarro, Giovambattista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853671/
https://www.ncbi.nlm.nih.gov/pubmed/24347984
http://dx.doi.org/10.4103/0976-500X.120963
_version_ 1782294669189709824
author Giofrè, Chiara
Scicchitano, Francesca
Palleria, Caterina
Mazzitello, Carmela
Ciriaco, Miriam
Gallelli, Luca
Paletta, Laura
Marrazzo, Giuseppina
Leporini, Christian
Ventrice, Pasquale
Carbone, Claudia
Saullo, Francesca
Rende, Pierandrea
Menniti, Michele
Mumoli, Laura
Chimirri, Serafina
Patanè, Marinella
Esposito, Stefania
Cilurzo, Felisa
Staltari, Orietta
Russo, Emilio
De Sarro, Giovambattista
author_facet Giofrè, Chiara
Scicchitano, Francesca
Palleria, Caterina
Mazzitello, Carmela
Ciriaco, Miriam
Gallelli, Luca
Paletta, Laura
Marrazzo, Giuseppina
Leporini, Christian
Ventrice, Pasquale
Carbone, Claudia
Saullo, Francesca
Rende, Pierandrea
Menniti, Michele
Mumoli, Laura
Chimirri, Serafina
Patanè, Marinella
Esposito, Stefania
Cilurzo, Felisa
Staltari, Orietta
Russo, Emilio
De Sarro, Giovambattista
author_sort Giofrè, Chiara
collection PubMed
description INTRODUCTION: Pharmacovigilance (PV) is designed to monitor drugs continuously after their commercialization, assessing and improving their safety profile. The main objective is to increase the spontaneous reporting of adverse drug reactions (ADRs), in order to have a wide variety of information. The Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) is financing several projects to increase reporting. In Calabria, a PV information center has been created in 2010. MATERIALS AND METHODS: We obtained data using the database of the National Health Information System AIFA relatively to Italy and Calabria in the year 2012. Descriptive statistics were performed to analyze the ADRs. RESULTS: A total number of 461 ADRs have been reported in the year 2012 with an increase of 234% compared with 2011 (138 reports). Hospital doctors are the main source of this reporting (51.62%). Sorafenib (Nexavar(®)), the combination of amoxicillin/clavulanic acid and ketoprofen represent the drugs most frequently reported causing adverse reactions. Adverse events in female patients (61.83%) were more frequently reported, whereas the age groups “41-65” (39.07%) and “over 65” (27.9%) were the most affected. CONCLUSIONS: Calabria has had a positive increase in the number of ADRs reported, although it has not yet reached the gold standard set by World Health Organization (about 600 reports), the data have shown that PV culture is making inroads in this region and that PV projects stimulating and increasing PV knowledge are needed.
format Online
Article
Text
id pubmed-3853671
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38536712013-12-16 Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis Giofrè, Chiara Scicchitano, Francesca Palleria, Caterina Mazzitello, Carmela Ciriaco, Miriam Gallelli, Luca Paletta, Laura Marrazzo, Giuseppina Leporini, Christian Ventrice, Pasquale Carbone, Claudia Saullo, Francesca Rende, Pierandrea Menniti, Michele Mumoli, Laura Chimirri, Serafina Patanè, Marinella Esposito, Stefania Cilurzo, Felisa Staltari, Orietta Russo, Emilio De Sarro, Giovambattista J Pharmacol Pharmacother Research Article INTRODUCTION: Pharmacovigilance (PV) is designed to monitor drugs continuously after their commercialization, assessing and improving their safety profile. The main objective is to increase the spontaneous reporting of adverse drug reactions (ADRs), in order to have a wide variety of information. The Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) is financing several projects to increase reporting. In Calabria, a PV information center has been created in 2010. MATERIALS AND METHODS: We obtained data using the database of the National Health Information System AIFA relatively to Italy and Calabria in the year 2012. Descriptive statistics were performed to analyze the ADRs. RESULTS: A total number of 461 ADRs have been reported in the year 2012 with an increase of 234% compared with 2011 (138 reports). Hospital doctors are the main source of this reporting (51.62%). Sorafenib (Nexavar(®)), the combination of amoxicillin/clavulanic acid and ketoprofen represent the drugs most frequently reported causing adverse reactions. Adverse events in female patients (61.83%) were more frequently reported, whereas the age groups “41-65” (39.07%) and “over 65” (27.9%) were the most affected. CONCLUSIONS: Calabria has had a positive increase in the number of ADRs reported, although it has not yet reached the gold standard set by World Health Organization (about 600 reports), the data have shown that PV culture is making inroads in this region and that PV projects stimulating and increasing PV knowledge are needed. Medknow Publications & Media Pvt Ltd 2013-12 /pmc/articles/PMC3853671/ /pubmed/24347984 http://dx.doi.org/10.4103/0976-500X.120963 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Giofrè, Chiara
Scicchitano, Francesca
Palleria, Caterina
Mazzitello, Carmela
Ciriaco, Miriam
Gallelli, Luca
Paletta, Laura
Marrazzo, Giuseppina
Leporini, Christian
Ventrice, Pasquale
Carbone, Claudia
Saullo, Francesca
Rende, Pierandrea
Menniti, Michele
Mumoli, Laura
Chimirri, Serafina
Patanè, Marinella
Esposito, Stefania
Cilurzo, Felisa
Staltari, Orietta
Russo, Emilio
De Sarro, Giovambattista
Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
title Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
title_full Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
title_fullStr Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
title_full_unstemmed Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
title_short Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
title_sort pharmacovigilance and drug safety in calabria (italy): 2012 adverse events analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853671/
https://www.ncbi.nlm.nih.gov/pubmed/24347984
http://dx.doi.org/10.4103/0976-500X.120963
work_keys_str_mv AT giofrechiara pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT scicchitanofrancesca pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT palleriacaterina pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT mazzitellocarmela pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT ciriacomiriam pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT gallelliluca pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT palettalaura pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT marrazzogiuseppina pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT leporinichristian pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT ventricepasquale pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT carboneclaudia pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT saullofrancesca pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT rendepierandrea pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT mennitimichele pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT mumolilaura pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT chimirriserafina pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT patanemarinella pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT espositostefania pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT cilurzofelisa pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT staltariorietta pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT russoemilio pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT desarrogiovambattista pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis
AT pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis